Navegar por autor "Bello López, José Luis"

A phase 2 study from spanish geltamo group investigating the efficacy and safety of bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Second interim analysis

2014- Bello López, José Luis

A point score simplification for practical use of the risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy

2013- Bello López, José Luis

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

2023- Mosquera Orgueira, Adrián; Díaz Arias, José; Serrano Martín, R.; Portela Piñeiro, V.; Cid López, Miguel; [et al.]

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia

2019- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Díaz Arias, José; Díaz Varela, Nicolás; Bello López, José Luis [et al.]

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia.

2019-11-07- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Díaz Arias, José; Díaz Varela, Nicolás; Bello López, José Luis [et al.]

ANALYSIS OF THE EFFICACY OF PHOTOPHERESIS IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR CORTICODEPENDENT EICH: EXPERIENCE OF A CENTRE

2015- Bello López, José Luis; Vilariño López, María Dolores; Villamayor Álvarez, Mercedes; Campos Pena, Alfredo

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

2019- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Alonso Vence, Natalia; Díaz Arias, José; Díaz Varela, Nicolás; [et al.]

Bendamustin as part of conditioning regimen for autologous stem cell transplantation (ASCT) in patients with aggressive lymphomas: A phase 2 study fromspanish geltamo group

2013- Bello López, José Luis

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

2019- Redondo, A. M.; Valcárcel, D.; González-Rodríguez, A. P.; Suárez-Lledó, M.; Bello López, José Luis; [et al.]

BEndamustine plus rituximab in first line systemic treatment for extranodal malt lymphoma: Final results of phase ii trial of the spanish lymphoma study group (geltamo)

2013- Bello López, José Luis

Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

2013- Debén Ariznavarreta, Guillermo; Bello López, José Luis

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2?R levels in non-Hodgkin's lymphoma

1999- Pérez Encinas, Manuel Mateo; Quintas, A.; Bendaña, A.; Rabuñal, M.J.; Bello López, José Luis [et al.]

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

2014- Constenla Figueiras, Manuel; López López, Rafael; Bello López, José Luis

Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes

2021- Mosquera Orgueira, Adrián; Ferreiro Ferro, Roi; Díaz Arias, José; Aliste Santos, Carlos; Antelo Rodríguez, Beatriz; [et al.]

Detection of rare germline variants in the genomes of patients with b-cell neoplasms

2021- Mosquera Orgueira, Adrián; Cid López, Miguel; Peleteiro Raindo, Andrés; Díaz Arias, José; Antelo Rodríguez, Beatriz; [et al.]

DO WE STILL NEED THE ALKYLATORS AS PART OF THE UPFRONT-TREATMENT OF ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS? UPDATED FOLLOW-UP OF GEM2005MAS65 SPANISH TRIAL COMPARING VMP VS VTP AS INDUCTION

2014- Bello López, José Luis

Do we still need the alkylators as part of the upfronttreatment of elderly newly diagnosed multiple myeloma patients? Updated follow-up of GEM2005MAS65 Spanish trial comparing VMP vs VTP as induction

2014- Bello López, José Luis

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

2014- Bello López, José Luis

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

2014- Bello López, José Luis

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia

2021- Mosquera Orgueira, Adrián; Peleteiro Raindo, Andrés; Cid López, Miguel; Antelo Rodríguez, Beatriz; Díaz Arias, José; [et al.]

Repositorio digital RUNA

Navegar por autor "Bello López, José Luis"

A phase 2 study from spanish geltamo group investigating the efficacy and safety of bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Second interim analysis ﻿

A point score simplification for practical use of the risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy ﻿

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma ﻿

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia ﻿

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia. ﻿

ANALYSIS OF THE EFFICACY OF PHOTOPHERESIS IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR CORTICODEPENDENT EICH: EXPERIENCE OF A CENTRE ﻿

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution ﻿

Bendamustin as part of conditioning regimen for autologous stem cell transplantation (ASCT) in patients with aggressive lymphomas: A phase 2 study fromspanish geltamo group ﻿

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group ﻿

BEndamustine plus rituximab in first line systemic treatment for extranodal malt lymphoma: Final results of phase ii trial of the spanish lymphoma study group (geltamo) ﻿

Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study) ﻿

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2?R levels in non-Hodgkin's lymphoma ﻿

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy ﻿

Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes ﻿

Detection of rare germline variants in the genomes of patients with b-cell neoplasms ﻿

DO WE STILL NEED THE ALKYLATORS AS PART OF THE UPFRONT-TREATMENT OF ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS? UPDATED FOLLOW-UP OF GEM2005MAS65 SPANISH TRIAL COMPARING VMP VS VTP AS INDUCTION ﻿

Do we still need the alkylators as part of the upfronttreatment of elderly newly diagnosed multiple myeloma patients? Updated follow-up of GEM2005MAS65 Spanish trial comparing VMP vs VTP as induction ﻿

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial ﻿

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? ﻿

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia ﻿

A phase 2 study from spanish geltamo group investigating the efficacy and safety of bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Second interim analysis

A point score simplification for practical use of the risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia.

ANALYSIS OF THE EFFICACY OF PHOTOPHERESIS IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR CORTICODEPENDENT EICH: EXPERIENCE OF A CENTRE

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

Bendamustin as part of conditioning regimen for autologous stem cell transplantation (ASCT) in patients with aggressive lymphomas: A phase 2 study fromspanish geltamo group

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

BEndamustine plus rituximab in first line systemic treatment for extranodal malt lymphoma: Final results of phase ii trial of the spanish lymphoma study group (geltamo)

Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2?R levels in non-Hodgkin's lymphoma

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes

Detection of rare germline variants in the genomes of patients with b-cell neoplasms

DO WE STILL NEED THE ALKYLATORS AS PART OF THE UPFRONT-TREATMENT OF ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS? UPDATED FOLLOW-UP OF GEM2005MAS65 SPANISH TRIAL COMPARING VMP VS VTP AS INDUCTION

Do we still need the alkylators as part of the upfronttreatment of elderly newly diagnosed multiple myeloma patients? Updated follow-up of GEM2005MAS65 Spanish trial comparing VMP vs VTP as induction

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia